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Case Report
Minimal Change Disease: A Case Report of an Unusual Relationship
Fahad Edrees1, Robert M. Black2,4, Laszlo Leb3,4, Helmut Rennke5
1

Department of Medicine, Division of Nephrology, Washington University School of Medicine,
Barnes Jewish Hospital, Saint Louis, MO, 2Division of Renal Medicine and 3Department of
Hematology Oncology, Saint Vincent Hospital, 4Reliant Medical Group, Worcester, 5Department
of Renal Pathology, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, USA
ABSTRACT. Kidney injury associated with lymphoproliferative disorders is rare, and the exact
pathogenetic mechanisms behind it are still poorly understood. Glomerular involvement presenting as a nephrotic syndrome has been reported, usually secondary to membranoproliferative
glomerulonephritis. We report a case of a 63-year-old male who presented with bilateral leg
swelling due to nephrotic syndrome and acute kidney injury. A kidney biopsy showed minimal
change disease with light chain deposition; however, no circulating light chains were present.
This prompted a bone marrow biopsy, which showed chronic lymphocytic leukemia (CLL) with
deposition of the same kappa monoclonal light chains. Three cycles of rituximab and methylprednisolone resulted in remission of both CLL and nephrotic syndrome, without recurrence
during a three-year follow-up.
Introduction
Minimal change disease (MCD) is the most
common cause of nephrotic syndrome in
children but it may occur in adults as well.
Although nephrotic syndrome can be associated with a number of solid and hematological
malignancies,1-5 the association with chronic
lymphocytic leukemia (CLL) is unusual. There
Correspondence to:

are only 18 reported cases of MCD with CLL
in the medical literature,4-8 and only one of
these patients had documented circulating
monoclonal light chains,6 we report a case of
MCD with kappa light chain deposition in the
mesangium without detectable urinary or
serum light chains. The nephrotic syndrome
responded to the treatment of CLL with rituximab and methylprednisolone.
Case Report

Dr. Fahad Edrees,
Washington University School of Medicine,
Barnes Jewish Hospital, St. Louis,
MO 63110, USA.
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The patient is a 63-year-old Caucasian male
with a history of coronary artery disease, heart
failure with preserved ejection fraction, hypertension, and chronic kidney disease with a

Minimal change disease: an unusual relationship

baseline serum creatinine of 1.5 mg/dL. He
presented to our hospital with shortness of
breath and lower extremity edema. On initial
examination, he was in no distress, blood
pressure 187/95 mm Hg, pulse 90 beats/min,
and O2 saturation was 95% on 2 L nasal
cannula. He had bilateral basal crackles and
soft pitting pedal edema up to the knees. The
remainder of the examination was unremarkable. Laboratory data showed a mild elevation of his creatinine to 1.74 mg/dL, mild
thrombocytopenia 120,000 with a normal white
blood cell count (WBC) of 7800/µL with normal differential count. Hemoglobin was 12.9
g/dL at this time. His urine dipstick showed 3+
protein. His serum albumin was 2.5 g/dL. His
lipid profile was normal except for elevated
triglycerides at 204 mg/dL. A random urine
estimated his protein excretion to be 9.7 g/day.
Renal ultrasound showed asymmetry with a
small kidney on the right. As a result, a renal
biopsy was canceled and he was placed on
methylprednisolone 48 mg/day for the idiopathic nephrotic syndrome and discharged
home. He had an initial response with a fall in
urinary protein to 1.5 g/day and improvement
in his edema.
At two months, he presented with worsening
proteinuria and edema despite continuing the
same dose of methylprednisolone with which
he was compliant by history. Cyclosporine was
added to his regimen. Serum creatinine increased
to 5.2 mg/dL following one day of cyclosporine administration, which was markedly
higher compared to 1.43 mg/dL three weeks
earlier. Urine sediment showed lipid and
abundant granular casts. Other abnormal tests
included BUN 174 mg/dL, hemoglobin (Hgb)
9.3 g/dL, and platelet count 152,000 µL, which
fell to 82,000 µL three days later. WBC remained normal. His renal function continued
to worsen and hemodialysis was initiated. At
this time, he underwent a percutaneous renal
biopsy which on electron microscopy showed
diffuse foot process effacement and scattered
small electron dense deposits present within
the mesangial matrix (Figure 1a and b). Immunofluorescence microscopy showed the segmental granular deposition of IgM (2+/4+),
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kappa light chains (2+/4+), no lambda light
chain reactivity, and trace C3 in the mesangial
areas (Figure 1c-e). Both serum and urine
immunofixation performed on two separate
occasions were negative. Free light chain ratio
was normal at 0.89 (normal 0.26–1.65). Because
of the IgM kappa deposits, he underwent a
bone marrow biopsy. The bone marrow aspirate and biopsy showed a B-cell monoclonal
population that was CD5, CD20, and CD23
positive (Figure 1f and g) with surface IgM
kappa immunoglobulin, representing 34% of
bone marrow cellularity, which was diagnostic
of CLL. Cytogenetics and fluorescence in situ
hybridization (FISH) studies showed that the
B lymphocytes had a deletion of 13q and
trisomy 12, characteristically associated with
CLL.
Based on these findings, treatment with
rituximab 375 mg/m2 once a week for four
weeks and methylprednisolone 1 g/m2 on the
first 3 days of the week was initiated. After
three cycles, his nephrotic syndrome improved
(urine protein excretion below 500 mg/day) and
his serum creatinine fell below 2 mg/dL; he no
longer required dialysis (Figure 2). The Hgb
and platelets increased to 13.2 and 153,000,
respectively. He has remained in remission
from nephrotic syndrome and CLL for over
three years without further treatment. However, he developed hypogammaglobulinemia
most likely secondary to rituximab treatment
with IgA 20 mg/dL (normal 81–463 mg/dL),
IgG 125 mg/dL (normal 694–1618 mg/dL),
and IgM <1 mg/dL (normal 48–271 mg/dL).
This has resolved after two years of conservative management.
Discussion
This is an unusual case of MCD secondary to
underlying CLL with no hematologic manifestations other than bone marrow and renal
involvement. The main clue to a hematological
disorder as the cause was the IgM kappa
deposition in the mesangium on renal biopsy.
While IgM nephropathy, evident by IgM
mesangial deposits on kidney biopsy, is a
common pattern of MCD, especially in children
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Figure 1. (a) Diffuse effacement of foot processes, ×4000 (red arrows in a and b). (b) Mesangial electron
dense deposits (asterix) ×6000. (c) Immunofluorescence positive for mesangial IgM deposits. (d and e)
Immunofluorescence shows the deposits are reactive for kappa but not lambda light chains. (f and g)
Bone morrow biopsy showing lymphocytes positive for CD20 and CD5.
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Figure 2. Protein/creatinine ratio over treatment
course.

and is usually associated with steroid resistant
or steroid dependent nephrotic syndrome.9
Staining is usually positive for both kappa and
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lambda. In contrast to the case of Alzamora,6 a
monoclonal protein was not detected in the
blood or urine of our patient. Identifying
mesangial deposition of monoclonal light
chains on renal biopsy in minimal chain disease should trigger a search for an underlying
lymphoproliferative disorder. The acute kidney injury was attributed to acute tubular necrosis, which has been observed in MCD10 and
was unlikely to be due to one day of
cyclosporine administration.
Of the 18 previously reported cases of CLL
with MCD, treatment was reported on 13 of
the patients (Table 1). Most were treated with
corticosteroids alone or in combination with
chlorambucil. Two of the previous cases were
treated with rituximab, one as initial treatment
and the other as second line after steroid plus
chlorambucil failed.5 Resolution of the nephrotic syndrome occurred in the first case but
not the second. While rituximab has been used
successfully to treat idiopathic MCD,16,17 the
deposition of monotypic immunoglobulin on

Table 1. Cases of chronic lymphocytic leukemia and minimal change disease that reported data about
treatment and outcome (13 cases).
Author
Kerkhoven 197311

Number
of cases
1

Seney 198612

2

Farrant 198813

1

Vivaldi 199214

1

Spalding 200115

1

Alzamora 20066

1

Kofman 20145

4

Treatment
Cs
Chlor
Cs
Cs followed by several
courses of chlor
Cs
Methylprednisolone, 2
cycles of COP
Cs and Chlor
Cs
Cs then Chlor. R/Cs
then F/Cs for relapse
Cs

Outcome
Remission of NS
Minimal decrease in serum creatinine
Remission of NS then relapse with renal
insufficiency
Remission of NS
Increase lymphocyte
Improved proteinuria, WBC, and creatinine
Remission of NS, normalized WBC count
Relapsed then remission after the second Cs
course
No resolution of proteinuria with all
treatments
Relapsed then remission of NS after the
second Cs course
Remission of NS
Persistent NS
Relapse that responded to chlor/Cs

Cs then R
No treatment
Poitou-Verkinder
2
Cs followed by
20158
chlor/Cs
NS: Nephrotic syndrome, WBC: White blood cell, Cs: Corticosteroid, Chlor: Chlorambucil, R:
Rituximab, F: Fludarabine, COP: Cyclophosphamide, vincristine, and prednisone.
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biopsy supports a secondary form of the disease.
The treatment of the underlying cause has been
associated with resolution of the nephrotic
syndrome in this setting. The combination
treatment of rituximab with methylprednisolone is an effective treatment for CLL and is
well tolerated.18 A major side effect of rituximab is hypogammaglobulinemia,19 which necessitates careful follow-up to detect infections
early.
Conclusion
The major significance of our case is that it
brings to light the importance of aggressively
pursuing the etiology of MCD in patients with
nephrotic syndrome with immunoglobulin deposition, even when serum and urine immunofixation and the WBC are normal.
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